TEMPO.CO, Jakarta - The US pharmaceutical company, Pfizer, earned sales up to US$7.8 billion or Rp112.3 trillion (reference exchange rate of Rp14,400) from the Covid-19 during the second quarter of 2021. This sales contributed to the company's profit increasing by 59 percent, to US$5.6 billion in the same period.
"This second quarter has been incredible," said Pfizer CEO Albert Bourla in a report on the official website on Wednesday, July 28, 2021.
In total, Pfizer earned US$18,9 billion in revenue during the second quarter of 2021. This number is up 92 percent compared to the second quarter of 2020.
Through this performance, the company raised its projection of vaccine sales by the end of the year by 29 percent. From a total of US$26 billion, to US$33.5 billion.
The increase in this projection is the result of the company sales contract in mid-July 2021 for 2.1 billion doses of vaccine. Meanwhile, the company will produce a total of 3 billion doses of the vaccine by the end of the year.
Pfizer is a company that produces the Covid-19 vaccine (BNT162b2) with German biotechnology company BioNTech. Currently, Bourla said, the company has distributed more than a billion doses of the vaccine globally.
Indonesia is also one of the recipients of this vaccine. Pfizer and BioNTech provide 50 million doses of Covid-19 vaccine for Indonesia throughout 2021. This vaccine has also received an emergency use authorization from the Food and Drug Supervisory Agency (BPOM).
FAJAR PEBRIANTO | MAUDEY K. SETYAKUSUMA